• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    7/21/23 1:31:07 PM ET
    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACGN alert in real time by email

    Gainers

    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 36.1% to $8.86 during Friday's regular session. As of 13:30 EST, Quoin Pharmaceuticals's stock is trading at a volume of 5.5 million, which is 27175.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.7 million.
    • Fresh Tracks Therapeutics (NASDAQ:FRTX) stock rose 33.54% to $0.91. Trading volume for Fresh Tracks Therapeutics's stock is 24.9 million as of 13:30 EST. This is 8375.3% of its average full-day volume over the last 100 days. The company's market cap stands at $5.3 million.
    • LifeMD (NASDAQ:LFMD) shares rose 26.34% to $4.46. As of 13:30 EST, this security is trading at a volume of 872.7K shares, making up 303.6% of its average full-day volume over the last 100 days. The company's market cap stands at $149.4 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 23.71% to $6.15. As of 13:30 EST, Biodexa Pharmaceuticals's stock is trading at a volume of 1.4 million, which is 532.5% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million.
    • bluebird bio (NASDAQ:BLUE) stock rose 18.8% to $4.17. bluebird bio's stock is trading at a volume of 7.6 million shares as of 13:30 EST. This is 181.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $443.7 million.
    • Fortress Biotech (NASDAQ:FBIO) stock increased by 15.92% to $0.6. As of 13:30 EST, Fortress Biotech's stock is trading at a volume of 4.1 million, which is 679.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $80.9 million.

    Losers

    • Redhill Biopharma (NASDAQ:RDHL) stock declined by 23.8% to $1.41 during Friday's regular session. Redhill Biopharma's stock is trading at a volume of 719.9K shares as of 13:30 EST. This is 387.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.5 million.
    • Mallinckrodt (AMEX:MNK) stock decreased by 16.21% to $0.48. Trading volume for this security as of 13:30 EST is 146.5K, which is 8.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.2 million.
    • Aceragen (NASDAQ:ACGN) shares declined by 15.08% to $1.07. The current volume of 237.8K shares is 79.4% of Aceragen's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $9.0 million.
    • BioSig Technologies (NASDAQ:BSGM) stock declined by 14.34% to $1.19. As of 13:30 EST, BioSig Technologies's stock is trading at a volume of 2.0 million, which is 313.5% of its average full-day volume over the last 100 days. The company's market cap stands at $88.1 million.
    • Avinger (NASDAQ:AVGR) stock declined by 14.29% to $0.9. Trading volume for Avinger's stock is 111.3K as of 13:30 EST. This is 43.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.6 million.
    • Novan (NASDAQ:NOVN) stock fell 13.52% to $0.14. Trading volume for Novan's stock is 1.6 million as of 13:30 EST. This is 177.0% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $AVGR
    $BDRX
    $BLUE

    CompanyDatePrice TargetRatingAnalyst
    LifeMD Inc.
    $LFMD
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    LifeMD Inc.
    $LFMD
    12/10/2024$12.00Buy
    Lake Street
    LifeMD Inc.
    $LFMD
    12/4/2024$7.00Neutral
    Mizuho
    bluebird bio Inc.
    $BLUE
    11/18/2024Neutral → Underweight
    Analyst
    bluebird bio Inc.
    $BLUE
    11/15/2024Neutral → Underweight
    JP Morgan
    bluebird bio Inc.
    $BLUE
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    More analyst ratings

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:24:03 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cooper Joseph Patrick

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:21:52 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Culverwell Anthony James

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:20:19 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

    March 9, 2026 Biodexa Announces Support for Life's a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated

    3/9/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeMD to Participate in Two Investor Conferences During March

    NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. Eastern time and a virtual panel titled "The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals" at 12:00 p.m. Eastern time. In addition, man

    3/3/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Bluebirdbio upgraded by Analyst

    Analyst upgraded Bluebirdbio from Underweight to Neutral

    2/24/25 7:05:14 AM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Bluebirdbio with a new price target

    Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

    2/24/25 7:04:33 AM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    SEC Filings

    View All

    SEC Form 10-K filed by LifeMD Inc.

    10-K - LifeMD, Inc. (0000948320) (Filer)

    3/10/26 4:56:58 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LifeMD, Inc. (0000948320) (Filer)

    3/9/26 4:37:40 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Financials

    Live finance-specific insights

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser

    2/23/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACGN
    $AVGR
    $BDRX
    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care